Investigational drug · Phase 2
STP938
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lymphoma, B-Cell, Lymphoma, T-Cell, Essential Thrombocythaemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "STP938"
First trial start
2022
Aug 3, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STP938", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoma, B-Cell
- Lymphoma, T-Cell
- Essential Thrombocythaemia
Approved drugs for the same conditions: Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "STP938" as an intervention, largest first.
Step Pharma, SASIndustry
NCT05463263 · 180 participants (planned) · Start Aug 3, 2022 · Primary completion Dec 2026
Drug: STP938 · For: Lymphoma, B-Cell; Lymphoma, T-Cell
Sites: Denver, Colorado; Sarasota, Florida; New York, New York · 15 sites in all
Step Pharma, SASIndustry
NCT06297525 · 70 participants (planned) · Start Aug 2, 2024 · Primary completion Dec 2026
Drug: STP938 · For: Solid Tumor
Sites: St. Petersburg, Florida; Dallas, Texas; San Antonio, Texas · 7 sites in all
Step Pharma, SASIndustry
NCT06786234 · 50 participants (planned) · Start Jun 18, 2025 · Primary completion Jun 30, 2028
Drug: STP938 · For: Essential Thrombocythaemia
Sites: Poitiers, France; Brest, France; Marseille, France · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CTPS1 promotes lung adenocarcinoma progression as a targetable vulnerability.
Xie H, Xu C, Zhou B, et al. · Br J Cancer 2026
- CTPS1 is an unexplored vulnerability in breast and ovarian cancer.
Wang X, Emch MJ, Voll LA, et al. · Theranostics 2026
- Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication.
Schrell L, Scheibner D, Dickmanns A, et al. · Antiviral Res 2025
- Synergistic interference with SARS-CoV-2 replication by molnupiravir-derived N4-hydroxycytidine and inhibitors of CTP synthetase in cell culture.
Stegmann KM, Dickmanns A, Fuchs HL, et al. · Virology 2025
- MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma.
Liang JH, Ren YM, Du KX, et al. · Br J Haematol 2023
Also in development for Lymphoma, B-Cell
- Rondecabtagene autoleucelLYL314Phase 32 trials
Lyell Immunopharma, Inc. · Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- JNJ-90014496Phase 21 trial
Johnson & Johnson (Janssen) · Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.